Despite the promise in whole‐tumor cell vaccines, a key challenge is to overcome the lack of
costimulatory signals. Here, agonistic‐antibody‐boosted tumor cell nanovaccines are …

Most cancer vaccines are unsuccessful in eliciting clinically relevant effects. Without using
exogenous antigens and adoptive cells, we show a concept of utilizing biologically …

Dendritic cell (DC)-based vaccines have shown promise in adoptive cell therapy for
enhancing the antigen-specific response of antitumor immunity. However, their clinical …

Dendritic cells (DCs)‐based vaccines are an approved method for inducing potent antigen‐
specific immune responses to eliminate tumor cells. However, this promising strategy still …

Engineering nanovaccines capable of targeting dendritic cells (DCs) is desperately required
to maximize antigen cross-presentation to effector immune cells, elicit strong immune …

Whole‐cell vaccines that provide broad‐spectrum antigens have been explored for recent
decades. But so far, they have revealed limited success in clinical trials, possibly owing to …

Neoantigen‐based immunotherapy is a promising treatment option for many types of cancer.
However, its efficacy and abscopal effect are limited by impotent neoantigens, high …

Recent breakthroughs in cancer immunotherapy offer new paradigm-shifting therapeutic
options for combating cancer. Personalized therapeutic anti-cancer vaccines training T cells …

Targeted immunomodulation through biomolecule‐based nanostructures, especially to
dendritic cells (DCs), holds great promise for effective cancer therapy. However, construction …

Tumor vaccines trigger tumor-specific immune responses to prevent or treat tumors by
activating the hosts' immune systems, and therefore, these vaccines have potential clinical …